The Economic Times
English EditionEnglish Editionहिन्दीગુજરાતી
| 12 August, 2020, 02:46 PM IST | E-Paper

    Kiran Kabtta Somvanshi

    Chief Manager - Economic Times Intelligence Group, ET

    Dr Kiran Somvanshi is a data journalist at The Economic Times. She has been a part of the research wing of ET for more than a decade and has written extensively on Indian companies and businesses. Te ...

    Read More

    Articles by the author

    In pharma, only the fittest will ride the crestMaking investment bets based on Covid pain or gain could be riskyAnalysis: A tale of three pharma companies and a quarterFive strategy lessons that FMCG companies can imbibe from Amul
    Pharma firms discover glamour in dowdy APIsSun Pharma resilient, may be a long-term buyAPI revenue surge turns Dr Reddy’s Covid negative in Q1ITC’s FMCG in line with view, but Cigarette business surprises Street
    Should Trump’s new executive orders on drug prices worry Indian pharmaceuticals?ETIG Analysis: Implications of the new Consumer Protection Act on consumer companiesGSK acquisition brings in some resilience in HUL’s Q1 earningsHUL’s Q1 show unlikely to give Street reason to turn more bullish
    In times of disruption, companies adapt supply chains to local realitiesTata Consumer’s shares doubled during lockdown; Is the dark horse worth a bet?ET Analysis: Is Asian Paints innovating or piling on non-core businesses?ETIG Analysis: Why is CSR set to turn from 'good to know' to 'need to know' for investors?
    How Covid-19 could transform the hospital businessITC remains a dividend play with FMCG bounce and Rs 20,000 crore cashAgile boards take lead in helping India Inc navigate Covid bumpsHealthcare staying fit offers no immunity to services
    No Chinese supply threat for drug companies, but scaling Great Wall is toughBetter compliance in US, improving finances augur well for Lupin stockNo Sun signs for investors, stock likely to stay underperformerSunrise deal can help make ITC a growth stock again
    Nestle to retain edge over HUL; high valuations to cap big upside thoughMNCs prove smarter in timing their exits from Indian stocksVolatility in input costs & currency to continue for HULHUL’s net may rise 17% in Q4 despite weak revenue forecast
    Investors can track 5 key events to make healthy return to StreetMNCs can improve valuations by listing Indian arms: ICICI SecuritiesWhy GCPL, Marico, Britannia & Emami missed the FMCG rallyTata Motors lone indian among top global R&D spenders
    Is India Inc. getting better sensitized on sexual harassment?Has Nifty’s composition kept pace with the changing Indian economy?Maternity law: Big companies unlikely to go slow on women hiringBan on e-cigarettes may actually benefit ITC
    Fall in Lupin post Nifty exit may be a chance to accumulate stockWhy India is justifiably perceived as the most unsafe place for women?Investors should focus on a director’s contribution, says Harsh MariwalaWill Sun Pharma get its mojo back on Dalal Street?
    50 not out! The long innings of India Inc chairmenITC beats estimates, but cigarette is under threatWill IHH Healthcare's acquisition of Fortis nurse it out of ICU?Headwinds ahead; how long can the HUL rally continue?
    Indian companies remain besotted with China
    The Economic Times